DIETARY-TREATMENT ELIMINATES SUCCINYLACETONE FROM THE URINE OF A PATIENT WITH TYROSINEMIA TYPE-1

被引:9
|
作者
BAIN, MD
PURKISS, P
JONES, M
BINGHAM, P
STACEY, TE
CHALMERS, RA
机构
[1] CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND
[2] NORTHWICK PK HOSP & CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND
关键词
Dietary treatment; Succinylacetone; Tyrosinaemia type 1;
D O I
10.1007/BF02034752
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Over an 18-month period serial observations of plasma tyrosine, methionine and urinary tyrosine metabolites were made and compared with urinary succinylacetone excretion in an infant with tyrosinaemia type 1 treated by diet alone. Despite broadly similar profiles there were significant temporal and quantitative differences between each of these metabolic parameters. Only when plasma tyrosine was kept in the low-normal range by strict phenylalanine restriction (10-15 mg phenylalanine/kg body weight) was detectable succinylacetone consistently eliminated from the urine. Urinary succinylacetone is the only measure of metabolite accumulation immediately proximal to the enzyme defect and its routine measurement will allow more effective control of dietary treatment. © 1990 Springer-Verlag.
引用
收藏
页码:637 / 639
页数:3
相关论文
共 50 条
  • [41] THE LACTATE CONCENTRATION OF THE URINE, A PARAMETER FOR THE ADEQUACY OF DIETARY-TREATMENT OF PATIENTS WITH GLUCOSE-6-PHOSPHATASE DEFICIENCY
    FERNANDES, J
    SMIT, GPA
    BERGER, R
    JOURNAL OF INHERITED METABOLIC DISEASE, 1984, 7 : 149 - 150
  • [42] Improved method to determine succinylacetone in dried blood spots for diagnosis of tyrosinemia type 1 using UPLC-MS/MS
    Al-Dirbashi, Osama Y.
    Rashed, Mohamed S.
    Jacob, Minnie
    Al-Ahaideb, Lujane Y.
    Al-Amoudi, Mohamed
    Rahbeeni, Zuhair
    Al-Sayed, Moeen M.
    Al-Hassnan, Zuhair
    Al-Owain, Mohamed
    Al-Zeidan, Hamad
    BIOMEDICAL CHROMATOGRAPHY, 2008, 22 (11) : 1181 - 1185
  • [43] A False-Negative Newborn Screen for Tyrosinemia Type 1-Need for Re-Evaluation of Newborn Screening with Succinylacetone
    Dijkstra, Allysa M.
    Evers-van Vliet, Kimber
    Heiner-Fokkema, M. Rebecca
    Bodewes, Frank A. J. A.
    Bos, Dennis K.
    Zsiros, Jozsef
    van Aerde, Koen J.
    Koop, Klaas
    van Spronsen, Francjan J.
    Lubout, Charlotte M. A.
    INTERNATIONAL JOURNAL OF NEONATAL SCREENING, 2023, 9 (04)
  • [44] LIPOPROTEIN MODIFICATIONS DURING DIETARY-TREATMENT IN PATIENTS WITH PRIMARY TYPE-V HYPERLIPOPROTEINEMIA
    MANZATO, E
    MARIN, R
    GASPAROTTO, A
    BAGGIO, G
    MARTINI, S
    GABELLI, C
    CREPALDI, G
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1986, 16 (02) : 149 - 156
  • [45] 2 MISSENSE MUTATIONS CAUSING TYROSINEMIA TYPE-1 WITH PRESENCE AND ABSENCE OF IMMUNOREACTIVE FUMARYLACETOACETASE
    ROOTWELT, H
    CHOU, J
    GHAL, WA
    BERGER, R
    COSKUN, T
    BRODTKORB, E
    KVITTINGEN, EA
    HUMAN GENETICS, 1994, 93 (06) : 615 - 619
  • [46] DEFICIENT ACTIVITY OF GLUCOCEREBROSIDASE IN URINE FROM PATIENTS WITH TYPE-1 GAUCHER DISEASE
    AERTS, JMFG
    DONKERKOOPMAN, WE
    KOOT, M
    BARRANGER, JA
    TAGER, JM
    SCHRAM, AW
    CLINICA CHIMICA ACTA, 1986, 158 (02) : 155 - 163
  • [47] PRENATAL-DIAGNOSIS OF TYPE-1 TYROSINEMIA BY MEASURING FUMARYLACETOACETASE ACTIVITY IN CHORIAL VILLOSITIES
    KVITTINGEN, E
    DIVRY, P
    MANDON, G
    ROLLAND, MO
    DOMENICHINI, Y
    GUIBAUD, P
    ARCHIVES FRANCAISES DE PEDIATRIE, 1986, 43 (07): : 530 - 530
  • [48] Heme as an initial treatment for severe decompensation in tyrosinemia type 1
    Neeleman, Rochus A.
    Wilson, J. H. Paul
    Williams, Monique
    Langendonk, Janneke G.
    GENETICS IN MEDICINE, 2020, 22 (02) : 437 - 438
  • [49] TREATING TYROSINEMIA TYPE 1: EXPERIENCE FROM KUWAIT
    Sameera, Sadeq
    Hanan, Bin Nakhi
    Niran, Al Naqeeb
    JOURNAL OF INHERITED METABOLIC DISEASE, 2011, 34 : S81 - S81
  • [50] HERPES-SIMPLEX VIRUS TYPE-1 FROM A PATIENT WITH RADICULONEUROPATHY
    MORRISON, RE
    SHATSKY, SA
    HOLMES, GE
    TOP, FH
    MARTINS, AN
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1979, 241 (04): : 393 - 394